As of September 30, 2026, REMEDY ENTMT OYJ carries a market capitalization of 268.17M, placing it among publicly traded companies globally. Its enterprise value stands at 260.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 268.17M |
| Enterprise Value | 260.77M |
REMEDY ENTMT OYJ's next confirmed earnings release is scheduled for February 5, 2027.
| Earnings Date | 2/5/2027 |
As of September 30, 2026, REMEDY ENTMT OYJ has 13.59M shares outstanding.
| Shares Outstanding | 13.59M |
These figures are as of September 30, 2026. The price-to-sales ratio is 4.11, and the price-to-book ratio stands at 4.29.
| PS Ratio | 4.11 |
| PB Ratio | 4.29 |
| P/TBV Ratio | 10.13 |
| P/FCF Ratio | -260.12 |
| P/OCF Ratio | -260.12 |
As of September 30, 2026, REMEDY ENTMT OYJ trades at an EV/EBITDA multiple of 52.62 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 260.77M versus a market cap of 268.17M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 4.62 |
| EV / EBITDA | 52.62 |
As of September 30, 2026, REMEDY ENTMT OYJ maintains a current ratio of 2.10, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.89, indicating elevated leverage, while an interest coverage ratio of 4.78 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.10 |
| Quick Ratio | 0.98 |
| Debt / Equity | 31.89 |
| Debt / EBITDA | 4.02 |
| Interest Coverage | 4.78 |
Over the twelve months ended September 30, 2026, REMEDY ENTMT OYJ posted a negative return on equity (ROE) of -5.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.65, reflecting losses generated across the asset base. The company generates approximately 145,822.19 in revenue per employee across its workforce of 387.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -5.93 |
| Return on Assets (ROA) | -3.65 |
| Revenue Per Employee | 145,822.19 |
| Employee Count | 387.00 |
Over the twelve months ended September 30, 2026, REMEDY ENTMT OYJ recorded an income tax benefit of -683,441.01 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -4.47M and -3.79M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -683,441.01 |
As of the close on November 6, 2026, REMEDY ENTMT OYJ's stock has gained approximately 4.85% over the past 52 weeks.
| 52-Week Price Change | 4.85% |
Over the twelve months ended September 30, 2026, REMEDY ENTMT OYJ generated 56.43M in revenue and converted that into -3.79M in net income, yielding earnings per share of -0.32. EBITDA reached 4.96M, while operating income came in at -3.82M.
| Revenue | 56.43M |
| Gross Profit | 31.98M |
| Operating Income | -3.82M |
| Pretax Income | -4.47M |
| Net Income | -3.79M |
| EBITDA | 4.96M |
| EBIT | -3.82M |
| Earnings Per Share (EPS) | -0.32 |
As of September 30, 2026, REMEDY ENTMT OYJ holds 27.34M in cash and equivalents against 19.94M in total debt, resulting in a net debt position of 6.57M. Total book value stands at 62.50M, with working capital of 30.71M providing operational flexibility.
| Cash & Cash Equivalents | 27.34M |
| Total Debt | 19.94M |
| Net Debt | 6.57M |
| Equity (Book Value) | 62.50M |
| Book Value Per Share | 4.60 |
| Working Capital | 30.71M |
REMEDY ENTMT OYJ produced -891,986.85 in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | -891,986.85 |
| Free Cash Flow | -891,986.85 |
| FCF Per Share | -0.08 |
Over the twelve months ended September 30, 2026, REMEDY ENTMT OYJ posted a gross margin of 56.68, reflecting its pricing power and cost economics. The operating margin of -6.76 and net profit margin of -6.72 provide insight into operational efficiency.
| Gross Margin | 56.68 |
| Operating Margin | -6.76 |
| Pretax Margin | -7.93 |
| Profit Margin | -6.72 |
| EBITDA Margin | 8.78 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -0.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.31, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to REMEDY ENTMT OYJ shareholders.
| Shareholder Yield | 0.31 |
| FCF Yield | -0.38 |
As of September 30, 2026, REMEDY ENTMT OYJ has an Altman Z-Score of 4.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.40 |
Already premium?